Recombinant Human BRD4 (N-10His-Flag) | PKSH033982

Recombinant Human BRD4 (N-10His-Flag) | PKSH033982 | Gentaur US, UK & Europe Disrtribition

Synonyms: HUNK1; HUNK1bromodomain-containing protein 4; HUNKI; MCAP

Active Protein: N/A

Activity: Recombinant Human Bromodomain-containing protein 4 is produced by our E.coli expression system and the target gene encoding Glu49-Glu460 is expressed with a 10His, Flag tag at the N-terminus.

Protein Construction: Recombinant Human Bromodomain-containing protein 4 is produced by our E.coli expression system and the target gene encoding Glu49-Glu460 is expressed with a 10His, Flag tag at the N-terminus.

Fusion Tag: N-10His-Flag

Species: Human

Expressed Host: E.coli

Shipping: This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at<-20°C.

Purity: > 95 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per µg as determined by the LAL method.

Stability and Storage: Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.

Molecular Mass: 49 kDa

Formulation: Supplied as a 0.2 μm filtered solution of 50mM HEPES, 200mM NaCl, 1mM DTT, 10% Glycerol, pH 7.5.

Reconstitution: Not Applicable

Background: Bromodomain-containing protein 4 (BRD4) is a member of the BET class chromatin reader proteins that bind acetylated histones and play a key role in transcriptional regulation and transmission of epigenetic memory. Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure. BRD bromodomains serve as recognition motifs for acetylated lysine residues on histones, while the NET domain may function by promoting phosphorylation of the C-terminal domain (CTD) of RNA Polymerase II. Some specific inhibitors of BRD4 that prevent binding to acetylated histones by binding Asn-140 and Asn-433 are promising therapeutic molecules for the treatment of leukemias. BRD4 is a potential therapeutic target in many diseases including breast cancer, AML, multiple myeloma, colon cancer and others.

Research Area: Cancer, epigenetics and nuclear signal